Sugi Predict

Sugi Predict / Targets / GUSB

GUSB

Beta-glucuronidase · P08236 · GUSB on Sugi Atlas →

36,247 patent compounds predicted against GUSB, 19,878 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL296097 SCHEMBL296097 1.00 11/20
SCHEMBL297069 SCHEMBL297069 0.67 11/20
SCHEMBL346502 SCHEMBL346502 0.60 11/20
SCHEMBL358545 SCHEMBL358545 0.46 10/20
SCHEMBL296062 SCHEMBL296062 0.70 9/20
SCHEMBL348930 SCHEMBL348930 0.55 8/20
SCHEMBL179040 SCHEMBL179040 0.71 7/20
SCHEMBL348123 SCHEMBL348123 0.66 7/20
SCHEMBL296222 SCHEMBL296222 0.56 7/20
SCHEMBL259479 SCHEMBL259479 0.56 7/20
SCHEMBL259417 SCHEMBL259417 0.50 7/20
SCHEMBL295717 SCHEMBL295717 0.48 7/20
SCHEMBL258433 SCHEMBL258433 0.78 6/20
SCHEMBL347506 SCHEMBL347506 0.60 6/20
SCHEMBL577954 SCHEMBL577954 0.60 6/20
SCHEMBL277488 SCHEMBL277488 0.51 6/20
SCHEMBL400070 SCHEMBL400070 0.73 5/20
SCHEMBL183430 SCHEMBL183430 0.59 5/20
SCHEMBL183953 SCHEMBL183953 0.59 5/20
SCHEMBL377758 SCHEMBL377758 0.59 5/20

Clinical trials — most relevant to GUSB by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease PHASE4COMPLETED
Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children PHASE4COMPLETED
High Dose or High Dose Frequency Study of Alglucosidase Alfa PHASE4COMPLETED
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) PHASE4UNKNOWN
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease PHASE3COMPLETED
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease PHASE3COMPLETED
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa PHASE3ACTIVE_NOT_RECRUITING
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer PHASE2COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN) PHASE1/PHASE2RECRUITING
A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II PHASE2COMPLETED
Avalglucosidase Alfa Extension Study PHASE2COMPLETED
Problems With Morphine Use in Patients With a Severe Brain Injury PHASE1/PHASE2UNKNOWN
Study of NK012 in Patients With Refractory Solid Tumors PHASE1COMPLETED
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors PHASE1COMPLETED
Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses nanCOMPLETED
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Effect of an Polyphenolic Beverage in Healthy Volunteers nanACTIVE_NOT_RECRUITING
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease nanAPPROVED_FOR_MARKETING
Assessment of Neurological Manifestations in Gaucher Disease Patients nanUNKNOWN
Registry Gangliosidoses nanUNKNOWN
Effect of Migalastat on Cardiac Involvement in Fabry Disease nanCOMPLETED
Immunome Project Consortium for Autoinflammatory Disorders nanCOMPLETED
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype nanUNKNOWN
Genetic Mapping of Atherogenic Lipoprotein Phenotypes nanCOMPLETED
Biomarker Analysis for GBA Associated Parkinson's Disease nanUNKNOWN
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GUSB binder may also engage these)

ProteinNameSimilarity
Q5R5N6 — 1.000 Q5R5N6 →
O77695 — 1.000 O77695 →
Q4FAT7 — 1.000 Q4FAT7 →
O97524 — 1.000 O97524 →
O18835 — 1.000 O18835 →
P06760 — 0.991 P06760 →
P12265 — 0.991 P12265 →
Q8K2I4 — 0.990 Q8K2I4 →
Q29444 — 0.986 Q29444 →
Q95327 — 0.984 Q95327 →
Q4FZV0 — 0.982 Q4FZV0 →
MANBA Beta-mannosidase 0.980 landscape →
Q58D55 — 0.978 Q58D55 →
Q6P1J0 — 0.978 Q6P1J0 →
Q99KR8 — 0.976 Q99KR8 →
Q10RB4 — 0.975 Q10RB4 →
P17164 — 0.975 P17164 →
Q60HF6 — 0.974 Q60HF6 →
P23780 — 0.974 P23780 →
FUCA2 Plasma alpha-L-fucosidase 0.974 landscape →
Q5R7P4 — 0.974 Q5R7P4 →
Q5RFI5 — 0.974 Q5RFI5 →
GAA Lysosomal alpha-glucosidase 0.974 landscape →
P45582 — 0.973 P45582 →
P70699 — 0.973 P70699 →
Q8BHN3 — 0.973 Q8BHN3 →
GLB1 Beta-galactosidase 0.973 landscape →
O19015 — 0.973 O19015 →
Q8IW92 — 0.973 Q8IW92 →
Q6ZJJ0 — 0.973 Q6ZJJ0 →